From: Altered kynurenine pathway metabolites in serum of chronic migraine patients
Healthy controls | Patients with CM | χ2/U | |
---|---|---|---|
(n = 84) | (n = 119) | p | |
Gender (F, %) | 69 (82.1) | 86 (72.3) | 2.66 0.071 |
Age (years; mean ± SD) | 40.4 ± 9.43 | 44.0 ± 11.6 | 4446 0.180 |
Trp (μg/ml) (mean ± SD) | 5.00 ± 1.55 | 5.27 ± 1.70 | 4198 0.052 |
KYN (μg/ml) (mean ± SD) | 0.34 ± 0.12 | 0.23 ± 0.09 | 2286 <0.001 |
KYNA (ng/ml) (mean ± SD) | 3.27 ± 1.85 | 2.46 ± 1.29 | 3692 0.002 |
ANA (ng/ml) (mean ± SD) | 2.28 ± 2.14 | 10.0 ± 5.92 | 565 <0.001 |
3-HK (ng/ml) (mean ± SD) | 2.39 ± 3.14 | 1.21 ± 0.69 | 3498 <0.001 |
3-HANA (ng/ml) (mean ± SD) | 9.11 ± 4.33 | 3.42 ± 1.40 | 553 <0.001 |
QUINA (ng/ml) (mean ± SD) | 18.2 ± 12.5 | 3.78 ± 3.34 | 580 <0.001 |
5-HIAA (ng/ml) (mean ± SD) | 32.6 ± 11.4 | 20.8 ± 8.16 | 1991 <0.001 |
XA (ng/ml) (mean ± SD) | 1.80 ± 1.01 | 2.30 ± 1.52 | 4108 0.048 |